Aggressive non-hodgkin's lymphoma, therapy with r-hypercvad and r-ara-c/mtx, contraindication to rituximab, switch to (r)hyper-CVAD
Item
1. patients with a diagnosis of previously untreated aggressive non-hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with r-hypercvad and r-ara-c/mtx. patients in whom rituximab is not used, due to contraindication, will be eligible. patients whose therapy was switched to (r)hyper-cvad after initial treatment with (r)chop, because of aggressive disease will also be eligible for the study.
boolean
C1332225 (UMLS CUI [1])
C1881081 (UMLS CUI [2])
C0393022 (UMLS CUI [3,1])
C0522473 (UMLS CUI [3,2])
C1742845 (UMLS CUI [4,1])
C0392747 (UMLS CUI [4,2])
Age
Item
2. patients age >/= 18 years.
boolean
C0001779 (UMLS CUI [1])
Karnofsky performance scale
Item
3. karnofsky performance scale >/= 70.
boolean
C0206065 (UMLS CUI [1])
ANC, platelet count, hemoglobin measurement, creatinine measurement, total bilirubin, sgpt
Item
4. adequate hematologic (anc >/= 1000/mm(3), platelet count >/= 100,000/mm(3) and hgb >/= 8gm/dl), renal (serum creatinine < 2mg/dl), and hepatic functions (total bilirubin </= 2 times, serum glutamate pyruvate transaminase (sgpt) or serum glutamate oxaloacetate transaminase (sgot) </= 3 times the upper limit of the respective normal range).
boolean
C0948762 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201913 (UMLS CUI [5])
C0201836 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
Contraceptive method
Item
5. patients (male and female) with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) must use adequate birth control.
boolean
C0700589 (UMLS CUI [1])
Informed consent
Item
6. institutional review board (irb)-approved signed informed consent.
boolean
C0021430 (UMLS CUI [1])
Gynaecological status
Item
1. pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
CNS involvement
Item
2. history of central nervous system (cns) involvement.
boolean
C0449389 (UMLS CUI [1])
Comorbidity
Item
3. co-morbid medical or psychiatric illnesses that preclude treatment with intense dose chemotherapy.
boolean
C0009488 (UMLS CUI [1])
Deep vein thrombosis or pulmonary embolus
Item
4. patients with history of deep vein thrombosis (dvt) or pulmonary embolus.
boolean
C0149871 (UMLS CUI [1])
C0034065 (UMLS CUI [2])
Platelet or bleeding disorders
Item
5. history of any platelet disorders including idiopathic thrombocytopenic purpura (itp), thrombotic thrombocytopenic purpura (ttp) or bleeding disorders.
boolean
C0005818 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
Prior Surgery or Radiation
Item
6. prior surgery or radiation therapy (rt) within 2 weeks of study entry.
boolean
C0744961 (UMLS CUI [1])
C0279134 (UMLS CUI [2])
NYHA, arrhythmia, myocardial ischemia, cerebrovascular accident
Item
7. patients with significant cardiac disease (new york heart association (nyha) class iii or iv), dysrrhythmia, or recent history of myocardial ischemia (mi) or ischemia, transient ischemic attack or cerebrovascular accident (cva) within the previous 6 months of study entry.
boolean
C1275491 (UMLS CUI [1])
C0003811 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0038454 (UMLS CUI [4])